167 related articles for article (PubMed ID: 19500098)
1. Natural polyphenols antagonize the antimyeloma activity of proteasome inhibitor bortezomib by direct chemical interaction.
Kim TY; Park J; Oh B; Min HJ; Jeong TS; Lee JH; Suh C; Cheong JW; Kim HJ; Yoon SS; Park SB; Lee DS;
Br J Haematol; 2009 Aug; 146(3):270-81. PubMed ID: 19500098
[TBL] [Abstract][Full Text] [Related]
2. Green tea polyphenols block the anticancer effects of bortezomib and other boronic acid-based proteasome inhibitors.
Golden EB; Lam PY; Kardosh A; Gaffney KJ; Cadenas E; Louie SG; Petasis NA; Chen TC; Schönthal AH
Blood; 2009 Jun; 113(23):5927-37. PubMed ID: 19190249
[TBL] [Abstract][Full Text] [Related]
3. Ascorbic acid inhibits antitumor activity of bortezomib in vivo.
Perrone G; Hideshima T; Ikeda H; Okawa Y; Calabrese E; Gorgun G; Santo L; Cirstea D; Raje N; Chauhan D; Baccarani M; Cavo M; Anderson KC
Leukemia; 2009 Sep; 23(9):1679-86. PubMed ID: 19369963
[TBL] [Abstract][Full Text] [Related]
4. Dietary flavonoids inhibit the anticancer effects of the proteasome inhibitor bortezomib.
Liu FT; Agrawal SG; Movasaghi Z; Wyatt PB; Rehman IU; Gribben JG; Newland AC; Jia L
Blood; 2008 Nov; 112(9):3835-46. PubMed ID: 18633129
[TBL] [Abstract][Full Text] [Related]
5. Pseudomembranous colitis following bortezomib therapy in a myeloma patient.
Moon SJ; Min CK; Lee DG; Lee S; Lee JW; Min WS; Kim CC; Kim M; Park G; Kim Y
Acta Haematol; 2007; 117(4):211-4. PubMed ID: 17237615
[TBL] [Abstract][Full Text] [Related]
6. Antimyeloma effects of arsenic trioxide are enhanced by melphalan, bortezomib and ascorbic acid.
Campbell RA; Sanchez E; Steinberg JA; Baritaki S; Gordon M; Wang C; Shalitin D; Chen H; Pang S; Bonavida B; Said J; Berenson JR
Br J Haematol; 2007 Aug; 138(4):467-78. PubMed ID: 17587338
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic use of tea derivatives: all that glitters is not gold.
Mancuso C; Barone E
Blood; 2009 Sep; 114(11):2359-60. PubMed ID: 19745081
[No Abstract] [Full Text] [Related]
8. Cooperation between Apo2L/TRAIL and bortezomib in multiple myeloma apoptosis.
Balsas P; López-Royuela N; Galán-Malo P; Anel A; Marzo I; Naval J
Biochem Pharmacol; 2009 Mar; 77(5):804-12. PubMed ID: 19100720
[TBL] [Abstract][Full Text] [Related]
9. Pulse treatment with the proteasome inhibitor bortezomib inhibits osteoclast resorptive activity in clinically relevant conditions.
Boissy P; Andersen TL; Lund T; Kupisiewicz K; Plesner T; Delaissé JM
Leuk Res; 2008 Nov; 32(11):1661-8. PubMed ID: 18394701
[TBL] [Abstract][Full Text] [Related]
10. Synergistic interaction of proteasome and topoisomerase II inhibition in multiple myeloma.
von Metzler I; Heider U; Mieth M; Lamottke B; Kaiser M; Jakob C; Sezer O
Exp Cell Res; 2009 Aug; 315(14):2471-8. PubMed ID: 19410573
[TBL] [Abstract][Full Text] [Related]
11. Arsenic trioxide and 2-methoxyestradiol reduce beta-catenin accumulation after proteasome inhibition and enhance the sensitivity of myeloma cells to Bortezomib.
Zhou L; Hou J; Fu W; Wang D; Yuan Z; Jiang H
Leuk Res; 2008 Nov; 32(11):1674-83. PubMed ID: 18485479
[TBL] [Abstract][Full Text] [Related]
12. The combined therapeutic effects of bortezomib and fenretinide on neuroblastoma cells involve endoplasmic reticulum stress response.
Pagnan G; Di Paolo D; Carosio R; Pastorino F; Marimpietri D; Brignole C; Pezzolo A; Loi M; Galietta LJ; Piccardi F; Cilli M; Nico B; Ribatti D; Pistoia V; Ponzoni M
Clin Cancer Res; 2009 Feb; 15(4):1199-209. PubMed ID: 19228726
[TBL] [Abstract][Full Text] [Related]
13. Effects of bortezomib on human neuroblastoma cells in vitro and in a metastatic xenograft model.
Valentiner U; Haane C; Nehmann N; Schumacher U
Anticancer Res; 2009 Apr; 29(4):1219-25. PubMed ID: 19414367
[TBL] [Abstract][Full Text] [Related]
14. Clinical and immunohistochemical features associated with a response to bortezomib in patients with multiple myeloma.
Dawson MA; Opat SS; Taouk Y; Donovan M; Zammit M; Monaghan K; Horvath N; Roberts AW; Prince HM; Hertzberg M; McLean CA; Spencer A
Clin Cancer Res; 2009 Jan; 15(2):714-22. PubMed ID: 19147779
[TBL] [Abstract][Full Text] [Related]
15. Bortezomib in combination with other therapies for the treatment of multiple myeloma.
Orlowski RZ
J Natl Compr Canc Netw; 2004 Nov; 2 Suppl 4():S16-20. PubMed ID: 19791424
[TBL] [Abstract][Full Text] [Related]
16. Bortezomib, dexamethasone, and fibroblast growth factor receptor 3-specific tyrosine kinase inhibitor in t(4;14) myeloma.
Bisping G; Wenning D; Kropff M; Gustavus D; Müller-Tidow C; Stelljes M; Munzert G; Hilberg F; Roth GJ; Stefanic M; Volpert S; Mesters RM; Berdel WE; Kienast J
Clin Cancer Res; 2009 Jan; 15(2):520-31. PubMed ID: 19147757
[TBL] [Abstract][Full Text] [Related]
17. Dietary Flavonoids with Catechol Moiety Inhibit Anticancer Action of Bortezomib: What about the other Boronic Acid-based Drugs?
Sak K
Curr Cancer Drug Targets; 2022; 22(9):741-748. PubMed ID: 35578889
[TBL] [Abstract][Full Text] [Related]
18. Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in cutaneous T cell lymphoma.
Heider U; Rademacher J; Lamottke B; Mieth M; Moebs M; von Metzler I; Assaf C; Sezer O
Eur J Haematol; 2009 Jun; 82(6):440-9. PubMed ID: 19220424
[TBL] [Abstract][Full Text] [Related]
19. Crystal structure of the boronic acid-based proteasome inhibitor bortezomib in complex with the yeast 20S proteasome.
Groll M; Berkers CR; Ploegh HL; Ovaa H
Structure; 2006 Mar; 14(3):451-6. PubMed ID: 16531229
[TBL] [Abstract][Full Text] [Related]
20. Oxidative deboronation of the peptide boronic acid proteasome inhibitor bortezomib: contributions from reactive oxygen species in this novel cytochrome P450 reaction.
Labutti J; Parsons I; Huang R; Miwa G; Gan LS; Daniels JS
Chem Res Toxicol; 2006 Apr; 19(4):539-46. PubMed ID: 16608165
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]